Dupont De Nemours Inc (DD)
Fair ValueFundamental
56
Price
$136.55
Market Cap
$18.11B
Part 1 · What the company is worth
Overview
DuPont is a global materials science and engineering company serving semiconductor fabrication, water treatment, worker safety, and construction markets. The company develops differentiated, high-performance materials and component solutions sold to industrial and consumer customers across approximately 50 countries.
How it makes money
DuPont generates revenue by selling specialty materials, engineered products, and component solutions. The Electronics & Industrial segment supplies semiconductor manufacturing materials, circuit board solutions, and packaging graphics to chipmakers and electronics manufacturers. The Water & Protection segment sells water filtration systems, protective equipment, and building materials under established brands including KEVLAR®, TYVEK®, NOMEX®, and FILMTEC™ to industrial, municipal, and consumer markets.
Revenue by segment
Supplies differentiated materials for semiconductor manufacturing, printed circuit boards, display materials, specialty silicones, and packaging solutions serving high-performance computing, 5G infrastructure, and electric vehicle manufacturers.
Provides water purification systems, worker safety and protective equipment, construction materials, and engineered solutions for municipal and industrial water treatment, occupational safety, and building weatherization applications.
Includes retained businesses in automotive adhesives and fluids, specialty polymers, and corporate overhead functions.
Competitive moat
Patents and licences · NarrowDuPont possesses established brands (KEVLAR®, NOMEX®, TYVEK®, FILMTEC™) that command customer loyalty in protective materials and water filtration, with high switching costs driven by industry standardization and qualification requirements. The company maintains a strong science and technology base with vertical integration across semiconductor manufacturing process steps. However, the moat is narrow: large competitors operate in adjacent areas, commodity price pressures exist in several product lines, and the semiconductor materials business faces cyclical demand. The Water & Protection segment revenue declined 4% in 2024 despite volume growth, indicating limited pricing power in some categories.
What drives demand
Moderately cyclicalDemand is moderate-cyclical. The Electronics & Industrial segment (48% of revenue) depends on semiconductor industry capital spending and consumer electronics replacement cycles, which are inherently cyclical. The segment benefits from secular growth trends: high-performance computing, 5G infrastructure development, and electric vehicle production are expanding. The Water & Protection segment (44% of revenue) is more defensive, driven by structural demand for water treatment and worker safety that persists through economic cycles. Municipal and industrial water treatment demand is less cyclical than electronics, though construction markets show cyclical behavior. Aggregate demand follows economic confidence: semiconductors and construction decline in recessions, but water treatment and safety equipment remain essential.
Key risks
- Separation execution risk — DuPont is pursuing a separation of its Electronics business which could result in operational disruption, management distraction, failed separation timing, or inability to complete the transaction. Such disruption could harm competitive position and financial performance.
- PFAS litigation and remediation costs — The company faces significant ongoing and potential future litigation related to PFAS chemical exposure and environmental contamination. As of December 31, 2024, DuPont has recorded an indemnification liability of $222 million for future eligible PFAS costs under its cost-sharing arrangement with Corteva and Chemours.
- Supply chain and input cost volatility — DuPont's profitability is vulnerable to disruptions in supply chains, increases in raw material costs, energy price fluctuations, and logistics costs. Supply chain disruptions, plant outages, labor shortages, and strikes could seriously harm operations.
- Geopolitical and trade risks — The company faces risks from trade disputes, tariffs, export controls, and geopolitical tensions, particularly regarding exports to China. Military conflicts and restrictions on regulated product exports could disrupt revenue and supply chains.
- Cyclical demand exposure — The Electronics & Industrial segment is exposed to cyclical demand from semiconductor fabrication, consumer electronics, and construction sectors. Economic downturns, reduced capital spending by chipmakers, and lower consumer electronics demand could significantly impact profitability.
The case for
Buyers argue that DuPont is well-positioned in secular growth markets. The semiconductor industry continues expanding to meet artificial intelligence and data center demand, supporting growth in high-performance computing materials. Electric vehicle adoption drives long-term demand for packaging and thermal management solutions. Global water scarcity and tightening environmental regulations support municipal and industrial water treatment demand. DuPont's established brands (KEVLAR®, NOMEX®, TYVEK®) command premium pricing and customer loyalty in protective equipment and filtration. The company is investing aggressively in capacity expansion ($70M Ohio semiconductor plant, $165M Newark expansion, $400M Luxembourg TYVEK® expansion), signaling management confidence in demand sustainability. The planned separation could unlock value by enabling focused strategies for each business. Free cash flow conversion exceeding 90% supports dividends and shareholder returns.
The case against
Sellers fear that DuPont faces significant execution risks. The planned Electronics separation could fail, delay, or prove disruptive to operations and competitiveness. The company carries a $222 million PFAS litigation liability with uncertain future costs, and environmental remediation obligations could expand. Supply chain vulnerability and commodity price inflation pressures margins: the company is dependent on volatile raw materials without clear pricing power in all segments (Water & Protection revenue declined 4% in 2024 despite volume growth). Semiconductor and construction end-markets are cyclical, and a recession would severely impact earnings. Geopolitical risks—particularly China export restrictions and trade tariffs—threaten a material portion of revenue. Competition from larger global specialty chemical companies and established competitors in protective materials limit pricing flexibility. The separation itself could strip DuPont of its large Electronics division (48% of revenue), leaving a smaller, less diversified company vulnerable to Water segment cyclicality.
Generated with artificial intelligence on September 21, 2026, shared with all users
Direct competitors
Who this company fights with for the same customers
Generated with artificial intelligence on September 18, 2026, shared with all users
3M sells protective garments and respiratory gear, medical-grade materials and filtration products to the same industrial, healthcare and safety buyers DuPont serves with Tyvek, Nomex and its medical packaging lines.
Toray is the main alternative supplier of reverse-osmosis and ultrafiltration membranes for desalination and municipal water plants, the market DuPont serves with its FilmTec membranes, and also competes in high-performance fibres.
Spun off from Honeywell in October 2025, Solstice sells Spectra protective fibre against DuPont's Kevlar in body armour and ropes, and Aclar barrier films against DuPont's healthcare packaging for pharmaceuticals and medical devices.
Teijin's Twaron and Technora para-aramid fibres go head to head with DuPont's Kevlar in ballistic protection, tyre reinforcement and friction materials, and both also supply polymers to medical customers.
Through its Hydranautics unit Nitto Denko builds reverse-osmosis and nanofiltration elements for the same desalination, industrial and municipal water projects DuPont's Water Solutions business bids for.
Saint-Gobain competes with DuPont twice over: its Life Sciences arm supplies silicone tubing and single-use components to biopharma customers alongside DuPont's Liveo line, while its building-materials business sells insulation and weather barriers against Tyvek and Styrofoam.
Balance Sheet & Liquidity
Revenue
$6.99B
Trailing 12 months (through 6/30/2026)
Net Income
$55M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$227M
Total Equity
$13.92B
Total Liabilities
$7.47B
Current Ratio
2.43
Interest Coverage
-
Debt/EBITDA
1.97
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$146.92
Current Price
$136.55
Margin of Safety
+7.1%
Fair Value Range
$107.56 - $186.27
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
160.65
ROE
-5.6%
P/B Ratio
1.34
P/FCF
26.27
Gross Margin
35.1%
ROIC
-
Profitability Radar
Value Creation (Economic Moat)
ROIC
-
WACC
8.9%
ROIC − WACC
-
Fundamental Analysis Criteria
Passed (13)
- Gross margin 35.1%
- P/FCF 26.27
- P/B ratio 1.34
- Debt/equity ratio
- Positive free cash flow
- Current ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Earnings surprise, average 4.3%
- Earnings quality (operating cash flow / net income) 18.93
- Share dilution 0.1%
- Net margin trend 0.8% vs -2.9%
- Piotroski F-Score 6/9
Failed (8)
- EPS shows upward trend
- Price CAGR 2.31%
- CapEx intensity
- Return on tangible assets
- Low reliance on intangibles
- Price below Graham Number
- ROE 0.3%
- Revenue growth 5Y -9.3%
Unavailable (5)
- ROIC –
- Dividend payout –
- Operating margin –
- Interest coverage
- PEG ratio (needs P/E > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Share count is stable
Institutional Holdings
No institutional filings reported for this company.
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Ms. Lori D. Koch | CEO & Director | 50 |
| Ms. Antonella B. Franzen | Senior VP & CFO | 49 |
| Mr. Erik T. Hoover J.D. | Senior VP & General Counsel | 51 |
| Mr. Christopher P. Raia | Chief Human Resources Officer | 55 |
| Mr. Jeroen Bloemhard | President of Healthcare & Water Technologies | 56 |
| Mr. David Koch | Chief Operations & Engineering Officer | - |
| Ms. Madeleine G. Barber | VP of Tax, Controller & Chief Accounting Officer | 61 |
| Mr. Marty DeGroot | Chief Technology Officer | - |
| Mr. Matthew S. Abbott | SVP, Chief Information Officer & Chief Procurement Officer | 48 |
| Ann Giancristoforo | VP of Investor Relations, Corporate FP&A, Strategic Finance | - |
Audit Risk
8
Board Risk
7
Compensation Risk
5
Shareholder Rights Risk
2
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-17
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-04
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-10
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much DD moves, measured on its daily prices.
More volatile than 12% of the tracked stocks (90-day volatility).
- Volatility 30d
- 20.5%
- Volatility 90d
- 22.0%
- Beta vs S&P 500 (1y)
- 1.06Correlation 0.45
- Max drawdown (12m)
- -19.6%
- ATR (14d, % of price)
- 2.07%
Earnings reactions
How DD moved around its past quarterly results.
Next earnings release
Nov 3, 2026 · In 10 days · Before the open
EPS estimate: 1.88Revenue estimate: $1.8B
What usually happens
- Over the last 12 releases the stock moved a median of 4.8% the next day, up or down.
- Next-day moves: up 10, down 2 (out of 12).
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Before the open | 1.81 | 1.88 | +3.7% | -7.8% | +1.2% | +0.2% |
| May 5, 2026 | Before the open | 1.50 | 1.65 | +10.3% | +1.6% | +8.4% | +11.4% |
| Feb 10, 2026 | Before the open | 1.33 | 1.38 | +3.5% | +2.6% | +4.9% | +8.0% |
| Nov 6, 2025 | Before the open | 3.28 | 3.27 | -0.2% | -1.0% | -1.2% | +2.9% |
| Aug 5, 2025 | Before the open | n/a | n/a | n/a | +6.8% | +2.4% | -1.4% |
| May 2, 2025 | Before the open | n/a | n/a | n/a | -0.4% | +1.8% | +0.3% |
| Feb 11, 2025 | Before the open | n/a | n/a | n/a | +4.6% | +6.8% | +10.6% |
| Nov 5, 2024 | Before the open | n/a | n/a | n/a | +3.8% | +4.7% | +2.2% |
| Jul 31, 2024 | Before the open | n/a | n/a | n/a | +4.2% | +4.1% | -2.9% |
| May 1, 2024 | Before the open | n/a | n/a | n/a | +6.1% | +8.0% | +9.4% |
| Feb 6, 2024 | Before the open | n/a | n/a | n/a | +5.3% | +7.4% | +11.9% |
| Nov 1, 2023 | Before the open | n/a | n/a | n/a | -4.1% | -8.2% | -6.1% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on DD and what the price did next.
- 4/9/2026NegativeWhat's Going On With DuPont Stock Thursday?
- +1 day
- -1.5%
- +3 days
- -3.0%
- 3/9/2026NegativeGoldman-Led Lenders Brace for Loss on Arclin Debt as Demand Cools
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
- 3/4/2026NegativeGoldman-Led Buyout Loan for DuPont Unit Struggles to Find Buyers
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for DD.
- 4/9/2026NEGATIVEWhat's Going On With DuPont Stock Thursday?
DuPont de Nemours, Inc. (DD) experienced a premarket decline, reflecting a broader softening in market risk appetite. While the article does not provide specific financial figures or catalysts, the downward price movement suggests investor caution. Traders will be monitoring key support levels and technical indicators for potential entry or exit points. The current market sentiment indicates a short-term bearish bias for DuPont stock, potentially influenced by macroeconomic factors or sector-specific headwinds.
- 3/9/2026NEGATIVEGoldman-Led Lenders Brace for Loss on Arclin Debt as Demand Cools
Goldman Sachs-led lenders are anticipating losses on debt financing for Arclin Inc.'s acquisition of DuPont's Aramids business. Investors have shied away from the deal due to concerns over the chemical industry's volatility and demand cooling. This situation suggests potential financial distress for Arclin and could impact the value of the acquired Aramids business, indirectly affecting DuPont's sale proceeds and reputation in future divestitures. The reluctance of lenders and investors highlights significant headwinds for the sector.
- 3/4/2026NEUTRALGoldman Further Sweetens Terms on Loan for DuPont Unit’s Sale
Goldman Sachs has further sweetened terms on a downsized $1.25 billion financing package for Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business. This move, despite the reduced financing amount, underscores ongoing struggles in the leveraged loan market. For investors, it signals a tight credit environment for complex M&A deals, potentially impacting valuations of similar transactions and companies' ability to fund strategic acquisitions through debt.
- 3/4/2026NEGATIVEGoldman-Led Buyout Loan for DuPont Unit Struggles to Find Buyers
The sale of risky debt is becoming increasingly challenging, as evidenced by the loan offering tied to Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business, backed by Goldman Sachs. The approximately $1.1 billion transaction is struggling to find buyers due to adverse market conditions for high-yield debt. This stalemate signals a growing risk aversion among investors, which could negatively impact future financing operations and valuations of companies reliant on this type of leverage. For DuPont, this might mean a revision of divestment plans or accepting less favorable terms.
- 2/20/2026NEUTRALGoldman Weighs Sweeter Terms on Loan Tied to DuPont Unit Sale
Goldman Sachs is considering improving terms on a $1.73 billion loan tied to Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business. This is a financing activity news, not directly impacting DuPont's stock value.